RxDoctor Payments Data

Sheila Blanks

Family · Jacksonville, NCNPI 1184985335

Payments from drug & device makers

$7,624in general payments, 2019–2025

Across 420 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$868
  • AbbVie$570
  • Teva Pharmaceuticals USA, Inc.$391
  • Jazz Pharmaceuticals Inc.$343
  • Eisai Inc.$312
  • Neurocrine Biosciences, Inc.$287
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$170%
  • Food & beverage$7,37897%
  • Education$2303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Harmony Biosciences LLC39$868
AbbVie51$570
Teva Pharmaceuticals USA, Inc.25$391
Jazz Pharmaceuticals Inc.18$343
Eisai Inc.16$312
Neurocrine Biosciences, Inc.16$287
Biogen13$275
UCB, Inc.10$251
Johnson & Johnson(2 entities)12$244
Neurelis, Inc.13$222
Avadel CNS Pharmaceuticals, LLC10$203
Lilly USA, LLC12$190
Avion Pharmaceuticals12$186
SK Life Science, Inc.6$186
Lundbeck LLC9$175
Argenx US, Inc.9$169
Boston Scientific5$169
Novartis11$169
Impel Pharmaceuticals Inc.8$167
Acorda Therapeutics, Inc10$157
Genentech USA, Inc.9$155
Mallinckrodt Hospital Products Inc.7$153
Amgen8$153
Axsome Therapeutics, Inc.6$144
Biohaven Pharmaceutical Holding Company Ltd.9$120
Acadia Pharmaceuticals Inc7$109
TG Therapeutics, Inc.5$101
Idorsia Pharmaceuticals US Inc5$94
Grifols USA, LLC5$91
Sanofi5$86
Pfizer5$74
Supernus Pharmaceuticals, Inc.5$70
AstraZeneca3$68
Catalyst Pharmaceuticals, Inc.2$46
Sunovion Pharmaceuticals Inc.3$44
Livanova USA, Inc.1$44
Merz Pharmaceuticals, LLC2$37
Azurity Pharmaceuticals, Inc.2$34
Avanir Pharmaceuticals, Inc.2$34
EMD Serono, Inc.2$34
Kyowa Kirin, Inc.2$33
Bristol Myers Squibb2$33
Intrabio Inc1$33
Takeda Pharmaceuticals U.S.A., Inc.1$33
Medtronic1$22
Springworks Therapeutics, Inc.1$21
CSL Behring1$21
Banner Life Sciences, LLC1$18
MDD US Operations, LLC1$18
Otsuka Pharmaceutical Development & Commercialization, Inc.1$18
Immedica Pharma US, Inc.1$17
Corium, LLC1$16
GRT US Holding, Inc.1$16
Biohaven Pharmaceuticals, Inc.1$16
Cala Health, Inc.1$15
Arbor Pharmaceuticals, Inc.1$15
Sumitomo Pharma America, Inc.1$14
Adamas Pharmaceuticals, Inc.1$14
Inspire Medical Systems, Inc.1$13
Aquestive Therapeutics, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,624 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$39,702
Medicare patients
208
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SabrilVigabatrin12$427,214
Kesimpta PenOfatumumab18$243,459
AptiomEslicarbazepine Acetate115$196,981
WakixPitolisant Hcl12$164,099
VimpatLacosamide69$82,788
KeppraLevetiracetam26$80,214
Lamictal XrLamotrigine35$78,728
FycompaPerampanel30$36,909
Aimovig AutoinjectorErenumab-Aooe37$35,147
Ajovy AutoinjectorFremanezumab-Vfrm24$34,404
Trokendi XrTopiramate21$28,807
LamictalLamotrigine25$28,725
XcopriCenobamate21$27,234
QuliptaAtogepant21$26,117
Oxtellar XrOxcarbazepine17$25,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lundbeck LLCSabril$175$427,21412 claims
Sunovion Pharmaceuticals Inc.Aptiom$44$196,981115 claims
Harmony Biosciences LLCWakix$868$164,09912 claims
UCB, Inc.Vimpat, Nayzilam$251$92,70980 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr, Oxtellar Xr$70$54,66738 claims
Eisai Inc.Fycompa$312$36,90930 claims
SK Life Science, Inc.Xcopri$186$27,23421 claims
AbbVieQulipta$570$26,11721 claims
PfizerNurtec Odt$74$15,99312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Jacksonville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →